Next Article in Journal
Phenolic-Enriched Collagen Fibrillar Coatings on Titanium Alloy to Promote Osteogenic Differentiation and Reduce Inflammation
Next Article in Special Issue
Heterogeneity of Neuroinflammatory Responses in Amyotrophic Lateral Sclerosis: A Challenge or an Opportunity?
Previous Article in Journal
Cellular and Subcellular Localisation of Kv4-Associated KChIP Proteins in the Rat Cerebellum
Previous Article in Special Issue
Dietary Wheat Amylase Trypsin Inhibitors Impact Alzheimer’s Disease Pathology in 5xFAD Model Mice
Review

Proteostasis and Proteotoxicity in the Network Medicine Era

Department of Science and High Technology and Center of Bioinformatics, University of Insubria, I-21052 Busto Arsizio, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(17), 6405; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21176405
Received: 5 August 2020 / Revised: 28 August 2020 / Accepted: 2 September 2020 / Published: 3 September 2020
(This article belongs to the Special Issue Proteotoxicity and Neurodegenerative Diseases)
Neurodegenerative proteinopathies are complex diseases that share some pathogenetic processes. One of these is the failure of the proteostasis network (PN), which includes all components involved in the synthesis, folding, and degradation of proteins, thus leading to the aberrant accumulation of toxic protein aggregates in neurons. The single components that belong to the three main modules of the PN are highly interconnected and can be considered as part of a single giant network. Several pharmacological strategies have been proposed to ameliorate neurodegeneration by targeting PN components. Nevertheless, effective disease-modifying therapies are still lacking. In this review article, after a general description of the PN and its failure in proteinopathies, we will focus on the available pharmacological tools to target proteostasis. In this context, we will discuss the main advantages of systems-based pharmacology in contrast to the classical targeted approach, by focusing on network pharmacology as a strategy to innovate rational drug design. View Full-Text
Keywords: neurodegeneration; proteostasis; systems biology; network medicine; network pharmacology neurodegeneration; proteostasis; systems biology; network medicine; network pharmacology
Show Figures

Figure 1

MDPI and ACS Style

Lualdi, M.; Alberio, T.; Fasano, M. Proteostasis and Proteotoxicity in the Network Medicine Era. Int. J. Mol. Sci. 2020, 21, 6405. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21176405

AMA Style

Lualdi M, Alberio T, Fasano M. Proteostasis and Proteotoxicity in the Network Medicine Era. International Journal of Molecular Sciences. 2020; 21(17):6405. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21176405

Chicago/Turabian Style

Lualdi, Marta, Tiziana Alberio, and Mauro Fasano. 2020. "Proteostasis and Proteotoxicity in the Network Medicine Era" International Journal of Molecular Sciences 21, no. 17: 6405. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21176405

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop